Patients Coming Off Anti-Obesity Jabs Regain Pounds Far More Rapidly Than Those on Conventional Diets

A recent study suggests that patients who come off new GLP-1 drugs like Mounjaro or Wegovy may regain lost weight far faster than those who halt conventional lifestyle programs.

Findings released in a leading medical journal points out that while obese individuals can lose a large proportion of their body weight while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month once they quit.

"People purchasing these drugs should be aware of the risk of rapid rebound weight gain when the therapy concludes," stated lead investigator Dr. Susan Jebb.

That rate of regain suggests a reversion to pre-treatment weight within about a year and a half.

Analyzing Therapies

The study, which reviewed 37 of studies involving thousands of participants, contrasted the effects of these new drugs with other pills.

The team emphasize that people who shed pounds through diet and exercise generally have a more gradual creep back—approximately 100 grams monthly—post-intervention.

The Reason for the Fast Rebound

Nutrition scientists believe the mechanism of the jabs is key to understanding the heightened weight return.

The injections imitate a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.

"Long-term administration of GLP-1 concentrations several times higher than the body's typical production might result in the body to produce less of its endogenous hormone, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.

"Stopping of this hormone supplement means appetite is no longer kept in check, making excessive eating much more probable."

A Lifelong Condition?

Health authorities suggest the injections for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.

Professionals contend that, due to the likelihood of relapse, the treatment is often ongoing.

This perspective is reinforced by pharmaceutical companies, who note that the findings "underscore the persistent character of excess weight," similar to managing conditions like hypertension.

Patient Experiences

People who have discontinued the jabs report a powerful resurgence of cravings.

"It was like a switch that goes on and you're instantly starving," recalled one woman.

This challenge is worsened if patients have not adopted lasting lifestyle or habit changes during therapy.

Growing Adoption

Survey data suggest that millions of adults in the UK have used these injections in the last 12 months, with demand remaining high.

• Use is more common among females compared to males.
• The middle-aged age group shows the highest usage rates.
• Many access the drugs through private healthcare rather than the NHS.

Ultimately, clinicians stress that while the jabs are potent tools for weight loss, they are not a permanent solution and lasting health benefits relies on integrated lifestyle support.